Abbott Laboratories Earnings - Q2 2026 Analysis & Highlights
Abbott Laboratories reported strong second quarter 2026 results with accelerating sales growth, margin expansion, and raised full-year guidance, driven by momentum across diagnostics, nutrition, and medical devices, while management emphasized durable healthcare demand and confidence in second-half acceleration despite macroeconomic concerns about procedure volumes.
Key Financial Results
Second quarter comparable sales growth of 4.8%, representing acceleration compared to the previous two quarters.
Adjusted earnings per share of $1.31, exceeding the midpoint of guidance range and consensus estimate.
Full-year comparable sales growth guidance reaffirmed at 6.5% to 7.5%, with EPS guidance raised to $5.45 to $5.60.
Adjusted gross margin of 58.0% of sales, representing an increase of 100 basis points compared to prior year.
Adjusted R&D at 6.9% of sales and adjusted SG&A at 28.6% of sales.
Third quarter adjusted EPS forecast of $1.38 to $1.46.
Foreign exchange had a favorable year-over-year impact of 0.8% on second quarter sales.
Business Segment Results
Diagnostics
Core laboratory US business grew 7.5%, with hospital labs specifically up 13% in the quarter.
Rapid and molecular diagnostics sales declined 8%, driven by anticipated decrease in respiratory virus testing due to weaker than normal season.
Cancer diagnostics sales growth of 13%, driven by mid-teens growth of Cologuard benefiting from growing base of new and repeat users.
Cologuard and Cologuard Plus reaffirmed as preferred screening options by American Cancer Society in May.
Nutrition
Sales increased sequentially by $125 million, driven by improving performance in both pediatric and adult nutrition.
International pediatric nutrition delivered growth of 6.5% in the quarter, first of nutrition businesses to transition back to positive growth.
US pediatric exited quarter with full benefit of recent WIC contract wins, with Abbott now market leader in both WIC and non-WIC segments.
US retail consumption of Ensure increased double digits compared to consumption levels exiting last year, achieving highest year-over-year consumption growth in past 1.5 years.
Emerging Pharma and Diagnostics (EPD)
Sales grew 9% in the quarter, reflecting broad-based growth across largest markets including India, Latin America, and Southeast Asia.
Medical Devices
Sales grew 8.5%, with cardiovascular device portfolio growth of 8.5% led by low-teens growth in electrophysiology and high single-digit growth in rhythm management and heart failure.
Electrophysiology marked beginning of acceleration in growth trajectory with launch of next-generation Volt PFA catheter in May.
Internationally, Volt and TactiFlex Duo rollout driving growth of more than 20% in Europe.
Rhythm management sales grew 9.5% as company continues to expand use of Aveir across pacemaker market segments.
Heart failure growth of 9% led by double-digit growth in US driven by market-leading portfolio of heart assist devices.
Continuous glucose monitoring sales exceeded $2 billion, reflecting growth of 9.5% in the quarter.
Libre Duo secured CE mark as world's first dual glucose ketone wearable sensor.
Capital Allocation
Cash generation and cash flow management likely to put company ahead of January forecast, allowing greater flexibility for capital return.
Industry Trends and Dynamics
Diagnostic test results inform approximately 70% of all healthcare decisions, making testing volumes reliable barometer of overall healthcare activity and demand.
US test volume data continues to reflect strong and stable demand for testing across United States and globally.
Durable demand for healthcare expected to continue accelerating due to aging population dynamics, with 10,000 people turning 65 daily in United States.
Structural tailwinds in emerging markets include expanding access to healthcare, aging populations, and rising need to treat acute and chronic conditions.
Demand for high-acuity life-saving products is very inelastic, with system treating people with serious acute medical conditions regardless of insurance status.
Competitive Landscape
Abbott's US cardio business performing better than ever, with strong stable demand both domestically and internationally.
Electrophysiology business gaining market share, with expectation to begin outperforming market and recapturing share in second half.
Left atrial appendage closure market is $2 billion market with competitor holding 90% market share, with Abbott focusing on market share capture.
Abbott positioned as only company with both stool and blood colorectal cancer screening tests, providing comprehensive portfolio advantage.
Macroeconomic Environment
Concerns about potential decelerating procedure volumes in US due to ACA disenrollment and Medicaid challenges are not supported by company data.
Medicaid is not primary driver of medtech surgical procedures in United States; Medicare is by far largest US payer, representing over two-thirds of Abbott's US cardio business.
Company did not see benefit from ACA expansion and Medicaid, so not expecting downside from potential disenrollment.
Exchange expected to have positive impact of approximately 1% on full year sales, including negative impact of approximately 1% on third quarter sales.
Growth Opportunities and Strategies
Product Pipeline and Launches
Completing patient enrollments in TECTONIC Coronary IVL Pivotal trial, completing FDA submission for Amulet 360 left atrial appendage device, and obtaining CE Mark for Libre Duo.
Anticipating launches of three new products along with TactiFlex Duo PFA catheter in US in steady cadence over next 12 months.
Beginning patient enrollment in fourth quarter for several important clinical trials including balloon expandable TAVR valve, leadless conduction system pacing device, mitral replacement valve from Cephea acquisition, peripheral IVL device from CSI acquisition, and wearable continuous lactate monitoring sensor.
New Ensure products featuring higher protein, lower sugar, and refreshed labeling and packaging contributing to sales growth.
Upcoming nutrition product launches include collagen protein shake, adult product with protein, H&B and creatine, and new infant formula using whole milk.
Continuous Glucose Monitoring Expansion
75 million to 80 million people worldwide could realistically be on CGM, with only 15 million currently using, providing significant growth opportunity.
Reimbursement expansion is primary driver for unlocking CGM opportunities, with active discussions with dozen or so countries to introduce or expand reimbursement.
US Type 2 reimbursement expansion could unlock around 10 million Medicare beneficiaries and accelerate commercial insurance coverage, representing multibillion-dollar opportunity.
France, Japan, and Canada have broadly adopted basal coverage expansion, with seven additional significant markets in discussions.
Company planning for fifth manufacturing facility, with $100 million sensor facility expected to reach capacity in next couple years, and $1 billion investment planned for fifth facility.
Exact Sciences Integration
Exact Sciences integration proceeding very well with no disruption, and team demonstrating strong understanding of market.
Care gap programs ramping in second half, helping health systems achieve HEDIS credits and CMR star ratings.
New Cologuard users exceeding expectations, with repeat user rescreen funnel expanding reliably.
International expansion opportunities for Cologuard with progress expected with certain governments.
Electrophysiology Strategy
Growth strategy focused on selling entire procedure, not just PFA catheters, including mapping systems, ancillary products, diagnostics, introducers, and ICE catheter.
Pipeline includes iterations and new versions of PFA catheters through 2029, with continued investment in mapping superiority.
Amulet 360 LAA device potential approval by year-end, with strong momentum expected into next year with rollout of TactiFlex Duo in US and continued Volt acceleration.
Structural Heart Improvements
Structural Heart expected to reach mid to high-single-digit growth rate by end of year, with personnel and market approach changes implemented.
International structural heart team delivering double-digit growth in first half, with TAVR up 30% and MitraClip, TriClip portfolio growing strongly.
Cephea mitral replacement valve showing incredibly positive feedback, with potential to fulfill promise of being as big as TAVR market.
Financial Guidance and Outlook
Full-Year 2026 Guidance
Comparable sales growth guidance of 6.5% to 7.5% maintained.
EPS guidance raised to $5.45 to $5.60.
Gross margin expansion expected to continue, supporting EPS guidance raise.
Segment Growth Outlook
Nutrition expected to grow in 2% to 4% range going forward.
Diagnostics portfolio with Exact Sciences addition and VBP impact subsiding viewed as 7% to 8% grower.
EPD business reliably delivering 7% to 9% growth for five years.
Medical devices viewed as 8% to 10% grower.
Combined segment ranges suggest 7% sustainable growth rate going forward.
Second Half 2026 Outlook
80% of second half lift coming from four areas: nutrition, electrophysiology, core lab, and cancer diagnostics, each entering with momentum and line of sight to business drivers.
Nutrition tracking slightly ahead of expectations with several strategies being executed well.
Core lab China business forecasted to decline in mid single digits versus prior 30% declines, allowing other businesses to overpower impact.
Cancer diagnostics showing very good trajectory especially with new Cologuard users.
Global EP growth expected to accelerate in second half and outperform market.
2027 and Beyond Outlook
7% sustainable top-line growth rate targeted despite much larger base today.
Only five healthcare companies with sales over $30 billion growing at least 7%, highlighting Abbott's differentiated portfolio.
Pipeline programs starting in Q4 expected to deliver contributions in 2029 and 2030.
